“…Sialic acid modifications not only impact therapeutic efficacy but also change the net charge of the protein. Since the publication of the CHO genome (Lewis et al, ), omics‐based approaches have successfully modified cell line productivity and quality (Bennun et al, ; Kuo et al, ; Lewis, Abu‐Absi, Borys, & Li, ). Recent works have shaped glycan profile by modifying glycosyltransferase activity (Yang, Wang, et al, ), sialyltransferase activity (Chung, Wang, Yang, Ponce, et al, ; Chung, Wang, Yang, Yin, et al, ; Könitzer et al, ), and lectin binding preference (Zhang, Luo, & Zhang, ) and knocking out GDP‐4‐keto‐6‐d‐deoxymannose epimerase/GDP‐4‐keto‐6‐l‐galactose reductase (FX) (Louie et al, ).…”